Lilly Covid Antibody Combo Gets U.S. Emergency Authorization
- Therapy seen as better able to combat coronavirus mutations
- Clearance is second gained by Lilly for antibody treatment
This article is for subscribers only.
Eli Lilly & Co.’s combination antibody drug for Covid-19 was cleared for emergency use by U.S. regulators, providing doctors with a treatment option that is expected to be better able to combat new coronavirus mutations.
The Food and Drug Administration authorized the treatment for use in Covid-positive adults and children 12 and older who are at high risk of developing severe forms of the disease or progressing to the hospital, according to a fact sheet posted Tuesday by the agency.